Trial reportDiabetes care2014
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Trial report in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus: a systematic review and meta-analysis.Hormones (Athens, Greece) · 2025Pooled it
- The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes.Frontiers in endocrinology · 2025Pooled it
- Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.Frontiers in endocrinology · 2020Pooled it
- Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.Diabetes, obesity & metabolism · 2020Trial
- The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.Journal of endocrinological investigation · 2018Trial
- Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.Diabetes care · 2016 · on this mapTrial
- Trial
- The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction.Journal of endocrinological investigation · 2025Review
- GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.EClinicalMedicine · 2024Review
- Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management.International journal of molecular sciences · 2024Review
- PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.Frontiers in pharmacology · 2023Article
- Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.Diabetology international · 2023Article
- Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Review
- Article
- Long term (4 years) improved insulin sensitivity following islet cell transplant in type 1 diabetes.Diabetes/metabolism research and reviews · 2018Article
- Adjunctive therapy for glucose control in patients with type 1 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Review
- Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events?Current diabetes reports · 2017Review
- Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Diabetes, obesity & metabolism · 2017Review
- Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Review
- The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.Journal of translational medicine · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveExenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes. RESEARCH DESIGN AND
methodsFourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period.
resultsHigh-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction.
conclusionsExenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.